Mike Bates

Angel Investor

2007

I formerly co-chaired the Life Science/MedTech group at the Band of Angels and the medical device screening committee at Life Science Angels. Medical Technology Investments: Advanced Cardiac Therapeutics (sold to Epix Ther 1X), Aerin Medical, AlterG, BlackSwan Vascular (~3X), Catheter Connections (assets sold to Merit Medical for no return), Cayenne Medical (sold to Zimmer Biomet 1.5X), Ciel Medical (sold to Vyaire 2X), CogENT Therapeutics (sold to Entellus 2.3X), CoLabs, CV Ingenuity (sold to Covidien 6X), Deep Blue Medical Advances, Figure 8 Surgical (defunct), Magnolia Medical, Materna, Moximed, Myoscience (sold to Pacira, no return), PercAssist, Pixel Optics (defunct), SI-Bone (IPO 2018), SafeBVM, SpineAlign Medical (defunct), TGS Knee Innovations (sold to Cayenne Medical no return), Tibion Robotics (sold to AlterG), Valfix, Visioneering (went public in AU, 0.25X) and Xpan. Biotechnology and Drug Development Investments: Inhalon Biopharma, Saccharo, Seal Rock Therapeutics, Mebias Discovery, Purissima (defunct) and Watershed Therapeutics. Internet and Web Services Investments: A6 Corporation (defunct), CareinSync (acquired by Hearst Health (0.8X), Everloop.com (defunct), Cabulous/Flywheel (defunct), HealthCrowd (8X), Mixbook.com, PharmaSecure (sold for tax loss), Practice Fusion (3.8X), Rapid Legal and Tenacity (defunct). Others: DecisionNext, Faraday Bicycles (sold to Pon 1.4X), Hi-Q Solar (bankrupt), iBeat (sold to Connect America 0.4X) , Luminari (defunct), Nanotech Biomachines (defunct), and S-2 Genomics

Director

2019

Surgical innovations in soft tissue surgery, aesthetics and to enhance hernia repair.

Director

2018 - 2023

BlackSwan Vascular developed an endovascular embolization system for the treatment of peripheral arterial hemorrage. The company received FDA Premarket Approval (PMA) of its Lava® Liquid Embolic System (Lava® LES) in April 2023 (the first such product to be cleared for use in the peripheral vasculature) and was acquired by Sirtex Medical shortly thereafter.

Chairman of the Board

2015 - 2018

Dextera Surgical, Inc. designed and manufactured proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures. I was appointed a Director and Chair of the Audit Committee in December of 2015 and Chairman of the Board in January 2016. I served in these roles until February 2018.

Consulting CFO

2008 - 2015

Moximed is developing a revolutionary new orthopedic medical device, the MISHA Knee System to treat osteoarthritis.

Board Member

2011 - 2013

Catheter Connections develops and markets innovative vascular access products that protect patients from life-threatening infections during infusion therapy.

Audit Committee Chairman; Board Member

2007 - 2012

A developer and marketer of a minimally invasive treatment to cure Barrett's esophagus, a pre-cancerous lesion of the esophagus. BARRX was backed by leading Medical Device venture capital firms and sold to Covidien in Jan. 2012.

Audit Committee Chairman; Board Member

2007 - 2011

Audit Committee Chairman; Board Member

2007 - 2009

Chief Financial Officer

2005 - 2007

SFMT was backed by USVP, Versant and Essex-Woodlands. We filed for an IPO in late 2006 and ran a dual track using JPMorgan as our financial advisor. The company was sold to Kyphon Inc. for $725 million in January 2007.